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Background: The AVERROES trial showed that apixaban reduced the risk of stroke or systemic embolism without significantly increasing the risk of 
major bleeding when used among atrial fibrillation (AF) patients unable or unwilling to take warfarin. This study evaluates the medical costs avoided 
with the use of apixaban vs. aspirin, based on the AVERROES trial. 
Methods: A cost comparison analysis was conducted from the US perspective to compare total medical costs associated with apixaban vs. 
aspirin use for AF. The rates of primary and secondary efficacy and safety endpoints were obtained from the AVERROES trial. Annual incremental 
costs associated with each clinical event were obtained from published literature and inflation adjusted to 2010 costs. Total medical costs were 
compared for apixaban vs. aspirin. Sensitivity analyses evaluated the variation in total medical cost avoidance with clinical endpoint rates and costs 
ranging within the confidence intervals (CI) and by +/- 20%, respectively. 
Results: Using AVERROES trial data, estimated efficacy and safety endpoint rates per patient year for apixaban were 1.43% [CI: 1.02-2.02] for 
ischemic or uncertain type of stroke (IS), 0.20% [CI: 0.07-0.56] for hemorrhagic stroke, 0.77% [CI: 0.45-1.33] for myocardial infarction (MI), and 
1.16% [CI: 0.82-1.54] for major bleeding excluding hemorrhagic stroke (MB). For each patient year, the estimated total medical cost reduction 
associated with apixaban use instead of aspirin was $655 with the largest cost reduction coming from IS ($546) and smaller reductions due to MI 
($77), systemic embolism ($55), and hemorrhagic stroke ($51). In contrast, apixaban use increased the overall cost of bleeding ($75), primarily due 
to MB ($71). The estimated total medical cost avoidance with apixaban vs. aspirin was consistent during sensitivity tests, ranging from $312-$854 
with varying model parameters. 
Conclusions: Based on AVERROES trial, among AF patients unable or unwilling to take warfarin, the use of apixaban instead of aspirin resulted 
in a net avoidance of $655 per patient year of total medical costs. The estimated cost avoidance was consistent when clinical event rates and 
associated costs were varied.
